Many months ago I noted that Lexaria offers a product that is either:
(a) unproven when targeting legitimate industries (nicotine, pharma, etc.), or
(b) proven when targeting an illegitimate industry (i.e., cannabis).
And that it was natural for it to "struggle" as a consequence.
As of last night, (b) is no longer true. ("For all intents and purposes" anyway - pending Royal Ascent.)
Good things are coming.
News 
Market Data 
Discover 
